Literature DB >> 31630334

Contemporary Issues in Pregnancy (and Offspring) in the Current HIV Era.

Allison Ross Eckard1, Stephanie E Kirk2, Nancy L Hagood2.   

Abstract

PURPOSE OF REVIEW: Although antiretroviral therapy (ART) has dramatically reduced mother to child transmission of HIV, data continue to mount that infants exposed to HIV in utero but are not infected (HEU) have serious negative health consequences compared to unexposed infants. This review evaluates recent literature on contemporary issues related to complications seen in pregnant women with HIV and their offspring. RECENT
FINDINGS: Current studies show that HEU infants are at a high risk of adverse outcomes, including premature birth, poor growth, neurodevelopmental impairment, immune dysfunction, infectious morbidity, and death. Etiologies for the observed clinical events and subclinical alterations are complex and multifactorial, and the long-term consequences of many findings are yet unknown. HEU infants have an unacceptable rate of morbidity and mortality from perinatal HIV and ART exposure, even in the modern ART era. Continual monitoring and reporting is imperative to protect this vulnerable population in our everchanging landscape of HIV treatment and prevention.

Entities:  

Keywords:  Antiretroviral therapy; Drug safety in pregnancy; HIV-exposed; Mitochondrial toxicity; Morbidity and mortality; Perinatal HIV; Uninfected infants

Year:  2019        PMID: 31630334      PMCID: PMC6938215          DOI: 10.1007/s11904-019-00465-2

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  97 in total

1.  Brief Report: Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008-2018.

Authors:  Virginia Rasi; Mario Cortina-Borja; Helen Peters; Rebecca Sconza; Claire Thorne
Journal:  J Acquir Immune Defic Syndr       Date:  2019-03-01       Impact factor: 3.731

2.  Comparison of auditory brainstem response in HIV-1 exposed and unexposed newborns and correlation with the maternal viral load and CD4+ cell counts.

Authors:  Ayotunde James Fasunla; Babatunde Oluwatosin Ogunbosi; Georgina Njideka Odaibo; Onyekwere George Benjamin Nwaorgu; Babafemi Taiwo; David Olufemi Olaleye; Kikelomo Osinusi; Robert Leo Murphy; Isaac Folorunso Adewole; Olusegun Olusina Akinyinka
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

Review 3.  Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.

Authors:  Binh Nguyen; Michelle M Foisy; Christine A Hughes
Journal:  Ann Pharmacother       Date:  2019-02-10       Impact factor: 3.154

4.  Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.

Authors:  Paige L Williams; Marilyn J Crain; Cenk Yildirim; Rohan Hazra; Russell B Van Dyke; Kenneth Rich; Jennifer S Read; Emma Stuard; Mobeen Rathore; Hermann A Mendez; D Heather Watts
Journal:  JAMA Pediatr       Date:  2015-01       Impact factor: 16.193

5.  Pregnancy Outcomes in the Era of Universal Antiretroviral Treatment in Sub-Saharan Africa (POISE Study).

Authors:  Sufia Dadabhai; Luis Gadama; Rachel Chamanga; Rachel Kawalazira; Chaplain Katumbi; Bonus Makanani; Dingase Dula; Nan Hua; Bryan Lau; Macpherson Mallewa; Taha E Taha
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

6.  A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children.

Authors:  Alana T Brennan; Rachael Bonawitz; Christopher J Gill; Donald M Thea; Mary Kleinman; Johanna Useem; Lindsey Garrison; Rachel Ceccarelli; Chinenye Udokwu; Lawrence Long; Matthew P Fox
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

7.  Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy.

Authors:  Grace A McComsey; Minhee Kang; Allison C Ross; Dirk Lebrecht; Elizabeth Livingston; Ann Melvin; Jane Hitti; Susan E Cohn; Ulrich A Walker
Journal:  HIV Clin Trials       Date:  2008 Mar-Apr

Review 8.  Linking Susceptibility to Infectious Diseases to Immune System Abnormalities among HIV-Exposed Uninfected Infants.

Authors:  Candice Ruck; Brian A Reikie; Arnaud Marchant; Tobias R Kollmann; Fatima Kakkar
Journal:  Front Immunol       Date:  2016-08-19       Impact factor: 7.561

9.  Growth of HIV-exposed uninfected, compared with HIV-unexposed, Zambian children: a longitudinal analysis from infancy to school age.

Authors:  Anna Rosala-Hallas; Jonathan W Bartlett; Suzanne Filteau
Journal:  BMC Pediatr       Date:  2017-03-16       Impact factor: 2.125

Review 10.  Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.

Authors:  Jean B Nachega; Olalekan A Uthman; Lynne M Mofenson; Jean R Anderson; Steve Kanters; Francoise Renaud; Nathan Ford; Shaffiq Essajee; Meg C Doherty; Edward J Mills
Journal:  J Acquir Immune Defic Syndr       Date:  2017-09-01       Impact factor: 3.731

View more
  3 in total

Review 1.  Maternal natural killer cells at the intersection between reproduction and mucosal immunity.

Authors:  Evgeniya V Shmeleva; Francesco Colucci
Journal:  Mucosal Immunol       Date:  2021-04-26       Impact factor: 7.313

2.  Neurobehavioural challenges experienced by HIV exposed infants: a study in South Africa.

Authors:  Gina Rencken; Pragashnie Govender; Catharina J E Uys
Journal:  BMC Pediatr       Date:  2022-08-06       Impact factor: 2.567

3.  Mitochondrial DNA Parameters in Blood of Infants Receiving Lopinavir/Ritonavir or Lamivudine Prophylaxis to Prevent Breastfeeding Transmission of HIV-1.

Authors:  Audrey Monnin; Nicolas Nagot; Marianne Periès; Roselyne Vallo; Nicolas Meda; Mandisa Singata-Madliki; James K Tumwine; Chipepo Kankasa; Nobubelo Ngandu; Ameena Goga; Pascal Reynier; Thorkild Tylleskär; Philippe Van de Perre; Jean-Pierre Molès
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.